MD Anderson and Amgen announce agreement to develop BiTE® therapies for myelodysplastic syndrome

(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Amgen have announced a research collaborative agreement focusing on Amgen's bispecific T cell engager (BiTE®) antibody constructs, an immunotherapy that serves as a 'bridge' between T cells and cancer cells.